493 related articles for article (PubMed ID: 29157669)
1. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H; Robak E
Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
[TBL] [Abstract][Full Text] [Related]
4. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
Gibiansky L; Frey N
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
[TBL] [Abstract][Full Text] [Related]
5. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.
Usón J; Balsa A; Pascual-Salcedo D; Cabezas JA; Gonzalez-Tarrio JM; Martín-Mola E; Fontan G
J Rheumatol; 1997 Nov; 24(11):2069-75. PubMed ID: 9375862
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
Clin Exp Rheumatol; 2003; 21(1):63-9. PubMed ID: 12673891
[TBL] [Abstract][Full Text] [Related]
8. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy.
Franke S; Herrmann D; Hein G; Müller A; Stein G
Eur J Med Res; 1997 Sep; 2(9):401-6. PubMed ID: 9300938
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
13. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
Chen F; Teachey DT; Pequignot E; Frey N; Porter D; Maude SL; Grupp SA; June CH; Melenhorst JJ; Lacey SF
J Immunol Methods; 2016 Jul; 434():1-8. PubMed ID: 27049586
[TBL] [Abstract][Full Text] [Related]
14. Similar serum levels of IL-6 and its soluble receptors in patients with HCV-related arthritis and rheumatoid arthritis: a pilot study.
Riccio A; Postiglione L; Sabatini P; Linvelli M; Soriente I; Sangiolo MG; Amato P; Tarantino G
Int J Immunopathol Pharmacol; 2012; 25(1):281-5. PubMed ID: 22507342
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
17. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.
Nishina N; Kikuchi J; Hashizume M; Yoshimoto K; Kameda H; Takeuchi T
Ann Rheum Dis; 2014 May; 73(5):945-7. PubMed ID: 24336338
[No Abstract] [Full Text] [Related]
18. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis.
Aizu M; Mizushima I; Nakazaki S; Nakashima A; Kato T; Murayama T; Kato S; Katsuki Y; Ogane K; Fujii H; Yamada K; Nomura H; Yachie A; Yamagishi M; Kawano M
Mod Rheumatol; 2018 Jul; 28(4):592-598. PubMed ID: 28880691
[TBL] [Abstract][Full Text] [Related]
20. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts.
Matsuno H
Mod Rheumatol; 2015 Jan; 25(1):38-42. PubMed ID: 25529071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
